Your Article Summary
Funding Biodefense Vaccine Development
BioPharm, 04/09/09
The development of a biodefense vaccine or a related product generally requires a significant investment, often in excess of $50 million. These funds are used for discovery, preclinical and clinical testing, development of a manufacturing process, and development and submission of the required regulatory-support documents. The funding process often begins with a grant-funded research project at a not-for-profit organization, such as a university, research center, or similar institution. If that research is successful, the resulting discovery must be transplanted to the commercial world for refinement, testing, regulatory approval, production, and distribution.
Today in Biotechnology...keeping you current
Receive free subspecialty "5-minute updates" via email
Sanofi-aventis and U.S Biotechnology company Alopexx enter into a collaboration agreement for a novel human monoclonal antibody targeting infectious diseases
Sanofi-aventis, 12/11/09
Quality by Design for Biotechnology Products—Part 2
BioPharm, 12/09/09
Amylin Pharmaceuticals to Present at the 2009 Deutsche Bank Biotech Boston Confab
Amylin Pharmaceuticals, 12/09/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
deCODE Discovers A Major Risk Factor for Type 2 Diabetes Dependent on Parent of Origin
deCODE genetics, 12/17/09
The Medtronic Foundation Offers Grants to Schools Participating in Online Sudden Cardiac Arrest Response Training
Medtronic, 12/17/09
AstraZeneca and the University of Virginia sign strategic research collaboration to develop novel treatments for cardiovascular disease
AstraZeneca, 12/16/09
Article Search
Sponsor


See Latest Articles


